‘No viscoat’ implantable collamer lens implantation

Session Details

Session Title: Posterior Chamber Phakic IOLs

Session Date/Time: Sunday 15/09/2019 | 14:00-16:00

Paper Time: 14:18

Venue: Free Paper Forum: Podium 3

First Author: : D.Lin CHINA

Co Author(s): :    M. Peng   L. Zhao   M. Khan                       

Abstract Details

Purpose:

To evaluate the efficacy, safety of “no viscoat” implantable contact lens (ICL) (Staar Collamer) implantation technique.

Setting:

Changsha Aier Eye Hospital, Aier Eye Institute of Central South University. No.388 Furong middle road, Changsha, China.

Methods:

A Staar Collamer posterior chamber phakic IOL with a central hole (ICL V4c) was implanted in 777 eyes of 526 patients with a mean age of 26 years(range 18 to 47 years). The mean preoperative axial was 27.04mm and anterior chamber depth was 3.27mm . We used balanced salt solution (BSS®) to load ICL and continuous perfusion with BSS to maintain the anterior chamber. Patients were followed up to 30 months. 777 eyes, 503 eyes, 249 eyes, 127 eyes and 38 eyes were followed up respectively for 1 month, 3 months, 6 months, 1 year and 2 years after operation.

Results:

Postoperatively, all eyes had a significant increase in uncorrected visual acuity(UCVA). The mean UCVA logMAR in 1 month, 3 months, 6 months, 1 year and 2 years was -0.02, -0.01, 0.03, 0.04 and 0.02 respectively. The intraocular pressure remained within normal range in all eyes and keep stable compared with preopration. The mean loss of central endothelial cell density (ECD) was 2.0%, 1.9%, 2.2%, 2.3%, 2.1% in 1 month, 3 months, 6 months, 1 year and 2 years respectively. None of the patients developed visually significant cataract.4 patients explant of ICL.

Conclusions:

“No viscoat” ICL implantation had good visual outcome and no significant changes in ECD, HEX and IOP. No visually significant cataract occurred during postoperative follow-up period. Long-term follow-up and more patients are required to confirm that significant complications do not occur in most patients over time.

Financial Disclosure:

None